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Pericytes, the mural cells of blood microvessels, have recently come into focus as regulators of vascular
morphogenesis and function during development, cardiovascular homeostasis, and disease. Pericytes are
implicated in the development of diabetic retinopathy and tissue fibrosis, and they are potential stromal
targets for cancer therapy. Some pericytes are probably mesenchymal stem or progenitor cells, which
give rise to adipocytes, cartilage, bone, and muscle. However, there is still confusion about the identity,
ontogeny, and progeny of pericytes. Here, we review the history of these investigations, indicate emerging
concepts, and point out problems and promise in the field of pericyte biology.Introduction
Although Eberth described their presence in 1871 (Eberth, 1871),
the discovery of pericytes is commonly assigned to the French
scientist Charles-Marie Benjamin Rouget, who two years later
described a population of contractile cells surrounding the endo-
thelial cells of small blood vessels (Rouget, 1873). Zimmermann
later called these cells ‘‘Rouget cells’’ and also coined the term
‘‘pericytes,’’ alluding to their location in close proximity to the
endothelial cells (Zimmermann, 1923). Between 1920 and 1950
numerous other publications described pericytes, some of
them, however, questioning the contractility of the cells (re-
viewed by Sims, 1986). Part of these discrepancies probably
had experimental reasons, but they may also reflect pericyte
heterogeneity and confusion about cell identities. Today, it is
clear that different cell types occupy the periendothelial com-
partments, yet that their correct identification is still challenging
(reviewed by Krueger and Bechmann, 2010).
The currently accepted definition of a mature pericyte as a cell
embedded within the vascular basement membrane (BM) came
with the application of electron microscopy (reviewed by Sims,
1986). As discussed below, this definition is difficult to apply
in situations of active angiogenesis. Another commonly applied
defining criterion is the presence in microvessels, i.e., capil-
laries, postcapillary venules, and terminal arterioles. Also, this
definition has been challenged by observations of subendothe-
lial pericyte-like cells in large vessels (reviewed by Dı´az-Flores
et al., 2009).
The periendothelial location of pericytes is frequently
confused with the periendothelial location of vascular smooth
muscle cells (vSMCs), fibroblasts, macrophages, and even
epithelial cells. Although the field has generally adopted the
view that pericytes belong to the same lineage and category of
cells as vSMCs, it should be remembered that there is no single
molecular marker known that can be used to unequivocally iden-
tify pericytes and distinguish them from vSMCs or other mesen-
chymal cells. The multiple markers that are commonly applied
are neither specific nor stable in their expression.As a result, the term pericyte is frequently used in the literature
to denote any microvascular periendothelial mesenchymal cell.
In fact, most published papers on pericytes do not investigate
whether they share BM with the endothelium and, to a large
part, do not succeed in distinguishing pericytes from other peri-
vascular cells. Current work on mesenchymal stem cells in the
blood vessel wall and their possible relation to pericytes is one
such area that we discuss further below. In fairness, the defini-
tion of a pericyte by criteria that requires ultrastructural analysis
for identification is not practical.
Thus, as a compromise pericytes are usually defined—or
described—using a mixture of criteria including location,
morphology, and gene/protein expression pattern. Below, we
highlight ambiguities concerning these criteria to help the reader
value a particular concept or result. We attempt to provide
a broad but brief base for the reader about the anatomy and
ontogeny of pericytes and of the signaling pathways involved
in pericyte recruitment and communication with the endothe-
lium. These are topics that have been covered in greater depth
in other recent reviews (Armulik et al., 2005; Gaengel et al.,
2009). We go into more detail concerning the physiology and
pathophysiology of pericytes, which are areas where significant
advances have been made recently. Whereas uncertainties con-
cerning cell lineages and identities remain, there is sufficient
available information to consider a scenario in which pericytes
play critical physiological roles in vascular development and
homeostasis, as sources of fibrogenic cells in pathological situ-
ations, and as a possible reservoir of stem or progenitor cells for
adult tissue repair.
Morphological Considerations
Shape and Location—a Continuum of Mural Cell
Phenotypes
Pericytes appear to be ubiquitously present in blood microves-
sels, but not normally in lymphatic capillaries. In certain devel-
opmental abnormalities, or pathological situations, lymphatic
capillaries may attract ectopic pericytes (Petrova et al., 2004).Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 193
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Figure 1. Pericyte Anatomy
(A) A continuum of mural cell cyto-architecture from
arteriole to venule. A single vSMC layer around
arterioles and precapillary arterioles encircles the
entire abluminal side of the endothelium. vSMCs
around arterioles have a flattened, spindle-shaped
appearance with few cytoplasmic processes,
whereas around precapillary arterioles the cell
bodies are distinctly protruding and extend several
processes encircling the endothelium. Pericytes
investing capillaries have a nearly rounded cell body
that gives rise to a few primary processes running
on the endothelium in the length of the capillary. The
primary processes give rise to secondary perpen-
dicular processes. The tips of secondary processes
attach firmly to the endothelium. On postcapillary
venules themural cell body flattens and gives rise to
many slender, branching processes. vSMCs cov-
ering venules have a relatively big, stellate shape
cell body with many branching processes, which,
unlike arteriolar vSMCs, do not wrap circularly
around the endothelium.
(B) Ultrastructural characteristics of pericytes and pericyte-endothelial interactions. Pericytes are rather anonymous in transmission electron microscopy. The
mature capillary pericyte (P) has a discoid nucleus that is surrounded by a small amount of cytoplasm containing protein-producing organelles andmitochondria.
Microtubules stretch along the primary and secondary cytoplasmic extensions. Intermediate filaments composed of desmin and vimentin are mostly
concentrated within in the primary extensions. Dense bands of microfilaments containing actin, myosin, and tropomyosin are concentrated beneath the plasma
membrane, in particular the inner surface membrane facing the endothelium. The outer, abluminal pericyte surface often shows numerous caveolae. Despite
being separated by the shared BM, pericytes and endothelial cells (E) make numerous direct contacts of different type: schematically depicted are peg-socket
contacts and adhesion plaques.
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minal surface of the endothelial tube. These processes usually
span several endothelial cells and occasionally bridge neigh-
boring capillary branches. At capillary branch points, which
commonly harbor a pericyte soma, primary processes are often
found to extend along each branch, conferring a cellular
Y-shape. Thin secondary processes extend from the primary
processes. These are usually perpendicular in their orientation
relative to the primary branches, thereby partially encircling the
vessel (Figure 1A).
Ultrastructure
The pericytes are enveloped in a BM that is continuous with the
endothelial BM. Pericytes probably contribute products to the
BM, and in vitro analysis demonstrates that pericyte-endothelial
interaction regulates BM assembly (Stratman et al., 2009, 2010).
Mature pericytes thus become embedded within a capillary
BM, a feature that makes it possible to identify primary and
secondary pericyte processes by transmission electrommicros-
copy in ultrathin sections (Sims, 1986). It is unclear to what extent
mature pericytes are always fully BM embedded. The literature
contains many descriptions of incomplete or even absent BM
coverage (reviewed by Dı´az-Flores et al., 2009). The relationship
between the pericyte and the microvascular BM is hard to see in
embryonic tissue or in pathological situations, where angiogen-
esis is active and the BM in a state of synthesis or turnover.
Here, the distinction between pericytes and other perivascular
mesenchymal cells is particularly problematic.
The majority of the pericyte-endothelial interface is separated
by a BM (Figure 1B). However, at discrete points, the two cell
types contact each other at holes in the BM. The number and
size of pericyte-endothelial contacts may vary between tissues,
but up to 1,000 contacts have been described for a single endo-
thelial cell. The contacts are of peg-socket type, in which peri-
cyte cytoplasmic fingers (pegs) are inserted into endothelial in-
vaginations (pockets). Other contact morphologies have been194 Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc.described, including sites where the two membranes come
very close together (close or occluding contacts). These are
located at the edge of the pericyte processes and possibly
play an anchoring role. Another type of contacts, referred to as
adhesion plaques, show microfilament bundles attached at the
pericyte plasma membrane and electron-dense material in the
opposing endothelial cytoplasm. They contain fibronectin and
resemble adherence junctions ultrastucturally. Possibly, these
are the sites where N-cadherin-based connections are formed
between endothelial cells and pericytes (Gerhardt and Betsholtz,
2003; Gerhardt et al., 2000). Gap junction-like structures have
also been reported at contacts between endothelial cells and
pericytes (Dı´az-Flores et al., 2009). These observations are
somewhat anecdotal, however, and functional evidence for
gap junctions between endothelial cells and pericytes exists
in vitro (Larson et al., 1987), but not in vivo. As discussed below,
the production of TGFb by endothelial and mural cells may
require their contact through gap junctions.
Pericyte Abundance
The pericyte density varies between different organs and
vascular beds, and the proportion of the endothelial abluminal
surface that is pericyte covered varies as well. The central ner-
vous system (CNS) vasculature is generally regarded as being
the most pericyte covered, with a 1:1–3:1 ratio between endo-
thelial cells and pericytes, and an approximately 30% coverage
of the abluminal surface (Mathiisen et al., 2010; Sims, 1986).
Significantly lower ratios have been reported for some other
tissues, e.g., human skeletal muscle, which has been stated to
have a 100:1 endothelial-to-pericyte ratio (reviewed in Dı´az-
Flores et al., 2009; Shepro and Morel, 1993). Although there is
undoubtedly variation, very low figures like this one are based
on singular reports and may be questioned since much higher
ratios have been described in skeletal muscle in other studies
(Tilton et al., 1979). If true, it would also imply that many endothe-
lial cells would be without pericyte contact, a situation that has
Figure 2. Examples of Pericyte Identification Using Different
Markers
(A) The vascular BM of a brain capillary identified by collagen IV (Col-IV, green)
and pericytes surrounding the endothelium by PDGFRb (red) immunostaining.
Note that the pericyte is embedded in vessel basement membrane, as seen by
the yellow appearance on the merged image. The white arrow points to a
typical pericyte cell body and the arrowheads indicate pericyte processes that
stretch horizontally along the capillary.
(B) A 3D view of brain endothelial cells (CD105, red) and pericytes (desmin,
green). Note the dissimilar appearance of pericytes compared to the one in (A),
which is due to the different marker used for identification. Desmin is an
intracellular intermediate filament protein, visualizing clustered intermediate
filaments, whereas PDGFRb is a transmembrane cell surface protein dis-
playing the pericyte membrane contour.
(C) Triple immunostaining of endothelium (CD31, blue) and mural cells
(NG2-green; aSMA -red) in the retina. vSMCs covering the vein (v) are positive
for aSMA and occasionally also for NG2, whereas pericytes surrounding the
capillaries are aSMA negative and NG2 positive.
(D) Epifluorescent image of retinal vessels of a promoter trap transgenicmouse
(XlacZ4) where pericyte nuclei are identified by X-gal staining (dark blue) and
cell bodies by NG2 staining (green). Endothelial cells are visualized by CD31
(red) staining. Note that all X-gal-positive cells are also positive for NG2. Red
arrowheads point to vSMCs covering the vein (v) and white arrowheads
indicate pericytes covering capillaries.
Scale bars represent 10 mm (A), 20 mm (B), and 50 mm (C and D).
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specific gene-targeted mouse mutants (see below). A conserva-
tive estimate based on available information is that endothelial-
to-pericyte ratios in normal tissues vary between 1:1 and 10:1
and that pericyte coverage of the endothelial abluminal surface
ranges between 70% and 10% (reviewed by Sims, 1986). These
differences are in part organ specific, and pericyte density and/
or coverage appears to correlate positively with endothelial bar-
rier properties (i.e., brain > lung > muscle), endothelial cell turn-
over (large coverage = less EC turnover) (Dı´az-Flores et al.,
2009), and orthostatic blood pressure (larger coverage in lower
body parts) (Sims et al., 1994). These observations are thus
consistent with a role of pericytes in regulating capillary barriers,
endothelial proliferation, and capillary diameter.Identification
Several recent reviews provide lists of molecular markers for
pericytes (Armulik et al., 2005; Dı´az-Flores et al., 2009; Krueger
and Bechmann, 2010) (examples shown in Figure 2). However,
not all markers are useful from a practical perspective. It is
also important to remember that no single entirely pericyte-
specific marker is known and that all markers currently used
are dynamic in their expression andmay be up or downregulated
in conjunction with developmental states, pathological reac-
tions, in vitro culturing, etc. A state-of-the-art identification of
pericytes in tissue sections or whole-mount preparations there-
fore relies on a combination of well-preserved tissue mor-
phology, counter-labeling of endothelial cells, and two or more
pericyte markers. Table 1 provides a list of currently validated
and often-used pericyte markers, as well as emerging and trans-
genic markers for murine studies.
Ontogeny of Pericytes
Early observations suggested that mural cells originate from
mesenchymal cells that condense on the abluminal side of the
endothelial tube (Clark and Clark, 1925), a scenario that has
been reinforced through later studies (Drake et al., 1998; Hunger-
ford and Little, 1999). However, while mature vSMCs have
a similar morphology and marker expression profile throughout
the vasculature, it is now clear from numerous lineage-tracing
studies that they have several different developmental origins,
making even a single vessel mosaic from a developmental point
of view (reviewed in Majesky, 2007; Majesky et al., 2011). For
example, vSMCs of the aorta and many of its proximal branches
have at least four different developmental origins—secondary
heart field, neural crest, somites, and splanchnic mesoderm—
contributions that largely follow a segmental pattern of
distribution.
Probably, the majority of the mural cells in the head region,
including all parts of the CNS, are neural crest derived, as
demonstrated in chick-quail chimeras (Bergwerff et al., 1998;
Etchevers et al., 2001; Korn et al., 2002) and indicated by marker
expression in mice (Heglind et al., 2005) (Figure 3). Recent
studies on thymus development demonstrated that also the
mural cells in the thymus are derived from neural crest (Foster
et al., 2008; Mu¨ller et al., 2008).
The origins of vascular mural cells in the gut (Wilm et al., 2005),
lung (Que et al., 2008), and liver (Asahina et al., 2011) have been
mapped to the mesothelium, the single-layer squamous epithe-
lium that lines the coelomic cavities and its organs. Coronary
vessel mural cells in the heart appear to have a similar develop-
ment. Here, the epicardial mesothelium is thought to give rise to
cardiac mesenchymal cells, including coronary vSMCs and peri-
cytes (Cai et al., 2008a; Dettman et al., 1998; Mikawa and Gour-
die, 1996; Wessels and Pe´rez-Pomares, 2004; Zhou et al., 2008)
(Figure 3).
Taken together, the above-mentioned work therefore sug-
gests that a common principle may exist for the development
of mural cells in coelomic organs. Here, mesothelial cells un-
dergo epithelial-to-mesenchymal transition (EMT), delaminate,
and migrate into the organs to produce their mesenchymal
components, including fibroblasts, vSMCs, and, most likely,
also the pericytes. Although the unequivocal identification of
the latter is problematic, as dicussed, available literatureDevelopmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 195
Table 1. Murine Pericyte Markers
Pericyte Marker
Gene
Symbol
Examples of Other Cell Types
Expressing the Marker Comments References
Validated Markers
PDGFR-b (platelet-
derived growth factor
receptor-beta)
Pdgfrb Interstitial mesenchymal cells
during development;
smooth muscle; in the CNS
certain neurons and neuronal
progenitors; myofibroblasts;
mesenchymal stem cells
Receptor tyrosine kinase;
functionally involved in
pericyte recruitment during
angiogenesis; useful
marker for brain pericytes
Lindahl et al., 1997;
Winkler et al., 2010
NG2 (chondroitin sulfate
proteoglycan 4)
Cspg4 Developing cartilage, bone,
muscle; early postnatal skin;
adult skin stem cells; adipocytes;
vSMCs; neuronal progenitors;
oligodendrocyte progenitors
Integral membrane
chondroitin sulfate
proteoglycan; involved in
pericyte recruitment to
tumor vasculature
Ozerdem et al., 2001;
Ruiter et al., 1993;
Huang et al., 2010
CD13 (alanyl (membrane)
aminopeptidase)
Anpep vSMCs, inflamed and tumor
endothelium; myeloid cells;
epithelial cells in the kidney,
gut
Type II membrane zinc-
dependent metalloprotease;
useful marker for brain
pericytes
Dermietzel and Krause, 1991;
Kunz et al., 1994
aSMA (alpha-smooth
muscle actin)
Acta2 Smooth muscle;
myofibroblasts;
myoepithlium
Structural protein;
quiescent pericytes do not
express aSMA (e.g., CNS);
expression in pericytes is
commonly upregulated in
tumors and in inflammation
Nehls and Drenckhahn, 1993
Desmin Des Skeletal, cardiac,
smooth muscle
Structural protein; useful
pericyte marker outside
skeletal muscle and heart
Nehls et al., 1992
New Markers Requiring Additional Validation
RGS5 (regulator of
G protein signaling 5)
Rgs5 Cardiomyocytes?; vSMCs Regulate heterotrimeric
G proteins by activating
GTPase activity; angiogenic
pericyte marker
Bondjers et al., 2003;
Cho et al., 2003
SUR2 (ATP-binding
cassette, subfamily
C (CFTR/MRP),
member 9)
Abcc9 Skeletal, cardiac, smooth
muscle; renal tubular
epithelium
Regulatory subunit of
ATP-sensitive potassium
channels
Bondjers et al., 2006
Kir6.1 (potassium
inwardly rectifying
channel, subfamily J,
member 8)
Kcnj8 vSMCs Associates with SUR2 Bondjers et al., 2006
Endosialin Cd248 vSMCs, myofibroblasts;
fibroblasts; T cells
Transmembrane cell
surface glycoprotein;
expression on pericytes
is dynamic; downregulated
during development
Christian et al., 2008
DLK1 (delta-like
1 homolog)
Dlk1 vSMCs; hepatoblasts in the
developing liver; adipocyte
progenitors
Transmembrane cell
surface protein
Bondjers et al., 2006
Transgenic Markers
XlacZ4 vSMCs, skeletal muscle
progenitors during
development
Expresses nuclear beta-
galactosidase in pericytes
and vSMCs; downregulated
in association with injury
Tidhar et al., 2001
NG2 dsRED vSMCs, oligodendrocyte
progenitors
BAC-transgene; reposited
in the Jackson Laboratory,
stock #008241
Zhu et al., 2008
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Figure 3. Developmental Origin of Mural Cells
Ectoderm-derived neural crest gives rise to vSMCs and pericytes in the CNS
and thymus (light blue). Mural cells in coleomic organs are all mesoderm- and
mesothelium-derived (violet). Epicardial mesothelium gives rise to mural cells
in heart, lung mesothelium to pericytes in the lung, etc. Note that vSMC
coverage around aorta has a multiple developmental origins, indicated by
different colors (yellow, secondary heart field; light blue, neural crest; green,
somite).
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Figure 4. Signaling Pathways Mediating Mural Cell Recruitment,
Differentiation, and Vascular Stabilization
Pericyte recruitment to the endothelium is mediated by multiple ligand-
receptor complexes: PDGF-B/PDGFRb, SDF-1a/CXC4R, HB-EGF/ErbB,
Shh/Ptc, and Ang1/Tie-2. The cellular response to TGFb/TGFbR signaling axis
is dependent on the composition of the receptor and the relative level of the
ligand. A ligand-receptor pair is indicated by the same color. N-cadherin and
Notch-mediated vessel stabilization requires direct contact between a peri-
cyte and an endothelial cell. Note that some signaling pathways are currently
only proposed to be relevant for pathological angiogenesis (see text for
details).
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organ. The mentioned studies also point to close ontogenic rela-
tionships between mural cells and fibroblasts in many organs,
supporting current ideas of such relationships also in patholog-
ical situations (discussed below). In spite of a mesothelial origin
of pericytes in diverse organs such as heart, lung, liver, and gut,
the signaling mechanisms that govern their recruitment into their
final periendothelial location may be different. This is exemplified
by the importance of PDGF-B/PDGFRb signaling (further dis-
cussed below), which has been demonstrated in heart, lung,
and gut, whereas the development of hepatic stellate cells (liver
pericytes) occurs independently of PDGF-B/PDGFRb (Hellstro¨m
et al., 1999). A similar distinction has beenmade for neural-crest-
derived pericytes, which depend on PDGF-B/PDGFRb signaling
in the CNS (Lindahl et al., 1997), but not in the thymus (Foster
et al., 2008).
Whereas some insights have thus been obtained into the
embryonic origin of pericytes in different organs, much less is
known about how pericytes grow and spread along growing
vessels in conjunction with developmental angiogenesis. Peri-
cytes proliferate during angiogenesis in the CNS and in vitro,
and the seeming lack of immature mesenchyme in the devel-
oping CNS would imply that new pericytes develop mainly by
proliferation of pre-existing ones in this organ. However, to
what extent new pericytes develop by division of pre-existing
pericytes—by recruitment (proliferation, migration, and differen-
tiation) from pre-existing vSMCs on neighboring large vessels
and/or by differentiation from immature mesenchyme, or
both—in most other organs are issues that are presently not
definitively resolved. The same holds true for the question about
ontogenetic relationships between pericytes and vSMCs. Thecontinuum of mural cell phenotypes observed along terminal
arterioles, capillaries, and postcapillary venules might suggest
that these cells can differentiate into each other in conjunction
with vessel growth and remodeling, but this also requires further
investigation.Signaling Pathways Implicated in the Development of
Pericytes and Their Interaction with Endothelial Cells
As discussed above, the anatomical relationship between peri-
cytes and endothelial cells suggests close interactions involving
paracrine or juxtacrine signaling (Figure 4). Endothelial-pericyte
signaling has recently been reviewed in detail (Gaengel et al.,
2009). Below we cover briefly this area and point out recent
advances in the understanding of how different intercellular sig-
naling pathways play a role in vascular development and
stability.
PDGF-B/PDGFRb
PDGF-B is released from angiogenic endothelial cells and binds
to PDGFRb expressed on the surface of developing pericytes. AsDevelopmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 197
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corecruited with the angiogenic sprouts. PDGFRb is expressed
broadly on developing vSMCs, and PDGF-B probably plays a
role also in the proliferation and differentiation of aortic and
venous vSMCs. Knockout of the pdgfb or pdgfrb genes in
mice results in virtually identical phenotypes and perinatal
lethality resulting from vascular dysfunction caused by mural
cell deficiency (Leve´en et al., 1994; Soriano, 1994). The degree
of this deficiency varies extensively between different organs,
suggesting that other signaling pathways may play a similar
role to that of PDGF-B/PDGFRb in mural cell recruitment. For
example, whereas the lack of pericytes in the brain, kidney,
lung, heart, and skin of pdgfb or pdgfrb knockout mouse
embryos is near total, the liver pericytes (stellate cells) are seem-
ingly unaffected (Hellstro¨m et al., 1999; Lindahl et al., 1997). As
discussed below, recent work suggests candidates for alterna-
tive endothelial-to-pericyte signaling pathways mediating peri-
cyte recruitment.
PDGF-B expression is not uniform in the developing endothe-
lium. Tip cells show higher PDGF-B expression than stalk cells.
Pericytes are immediately attracted to emerging angiogenic
sprouts and are usually lagging only slightly behind the tip cells
(Gerhardt and Betsholtz, 2003). Developing arteries also express
higher levels of PDGF-B mRNA than corresponding veins in
correlation with the thickness of the mural cell coat. However,
the importance of differential levels of PDGF-B expression in
different endothelial cells is uncertain. The phenotype of a
complete pdgfb knockout was rescued by re-expression of
PDGF-B in endothelial cells from the Rosa26 promoter (Armulik
et al., 2010), which would be assumed to provide similar levels of
PDGF-B expression in all endothelial cells.
Once secreted, PDGF-B is normally bound to the extracellular
matrix (reviewed by Andrae et al., 2008). This binding is con-
ferred by a C-terminal retention motif (Ostman et al., 1991),
which has affinity for heparin and heparan sulfate proteoglycans
(HSPGs) (Abramsson et al., 2007; Kurup et al., 2006). Targeted
deletion of the retention motif in mice (pdgfbret/ret) leads to hypo-
plasia and partial detachment of pericytes (Lindblom et al.,
2003), suggesting that PDGF-B needs to be presented as a
cell surface or matrix-bound factor in order to exert a proper
signal for pericyte recruitment to the vessel wall. This scenario
is supported by global reduction of N-sulfated heparan sulfate
generated by knockout of the N-deacetylase/N-sulfotransferase
(NDST)-1 enzyme, which leads to a delay in recruitment and
partial detachment of pericytes (Abramsson et al., 2007). Prob-
ably, endothelial HSPGs are critical since pericyte-specific abla-
tion of heparan sulfate did not interfere with pericyte recruitment
into the developing CNS (Stenzel et al., 2009).
Although most studies have focused on embryonic develop-
ment, there is also evidence that PDGF-B/PDGFRb signaling
plays a role postnatally. Constitutive activation of PDGFRb by
targeted insertion of an activating mutation in the pdgfrb locus
in mice was shown to promote proliferation and inhibit differen-
tiation in mural cells (Olson and Soriano, 2011), leading to post-
natal phenotypes that are further discussed below. The impor-
tance of PDGF-B for pericyte recruitment to tumors is also
discussed below. A recent report suggests that PDGF-B medi-
ates mural cell recruitment and vessel maturation in response
to the drug thalidomide in patients with hereditary hemorrhagic198 Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc.telangectasia and in mouse models of the disease (Lebrin
et al., 2010). Thalidomide has previously been proposed to
have antiangiogenic activities, but conflicting data have been re-
ported regarding these effects and mechanisms have not been
elucidated (Bauer et al., 1998).
TGFb
TGFb signaling has been implicated in the induction of mural cell
formation from undifferentiated mesenchyme, in mural cell pro-
liferation and differentiation, and in the regulation of endothelial
cell proliferation and differentiation. Both endothelial cells and
mural cells express TGFb, but its activation from a latent proform
appears to require collaboration between the two cell types (Sato
and Rifkin, 1989). Likewise, TGFb receptors are expressed on
both cell types. Thus, the role of TGFb signaling in vascular devel-
opment, maintenance, and function is complex. It is difficult to
sort out the primary roles of TGFb signaling in each cell compart-
ment, since they are interdependent, and as an inevitable con-
sequence, affecting one will secondarily affect the other. A large
number of studies ranging from in vitro models using single cell
typesor cocultures to in vivowork utilizinggain- and loss-of-func-
tion genetic approaches have demonstrated the pivotal role of
TGFb signaling,membersof theTGFb signalingpathway, andup-
steam regulators and modifiers of TGFb signaling in vascular
development (reviewed by Gaengel et al., 2009).
Two distinct type I TGFb receptors—activin receptor-like
kinase (Alk)-1 and Alk-5—are expressed in both endothelial
cells and mural cells and the two receptors appear to trigger
different—even opposing—cellular effects (Goumans et al.,
2002, 2003; Oh et al., 2000). Activation of Alk-5 in mesenchymal
cells leads to phosphorylation of Smad2/3-promoting mitotic
and migratory quiescence and differentiation into SMC. Activa-
tion of Alk-1 on the other hand leads to phosphorylation of
Smad1/5 and the induction of target genes that promote cell
proliferation and migration, and it opposes SMC differentiation
(Chen et al., 2003; Goumans et al., 2002; Ota et al., 2002). In
endothelial cells, a complex interplay between Alk-1 and Alk-5
signaling has been suggested, in which Alk-1 inhibits Alk-5,
whereas Alk-5 at the same time is required for Alk-1 signaling.
Overall, Alk-5 seems to promote vessel maturation, whereas
Alk-1 has the opposite effect. The net effect of TGFb may
depend on the relative levels of Alk-1/5 expression but also on
the strength and duration of the TGFb signal. Alk-1 signaling
may dominate in the early phase of TGFb stimulation, leading
to cell proliferation and migration, whereas Alk-5 signaling domi-
nates later, leading to cell differentiation and extracellular matrix
production. Knockout of most of the different TGFb signaling
pathway genes in mice, e.g., tgfb1 (Dickson et al., 1995), alk1
(Urness et al., 2000), alk5 (Larsson et al., 2001), tgfbr2 (Oshima
et al., 1996), smad4 (Lan et al., 2007), smad5 (Chang et al.,
1999; Yang et al., 1999), and endoglin (Li et al., 1999), leads to
embryonic lethality at midgestation with severe vascular abnor-
malities, including remodeling defects in the yolk sac vascula-
ture, arterio-venous anastomoses, defective formation of mural
cells, and—in some mutants—defective hematopoiesis. In hu-
mans,mutations inENDOGLIN,ALK1, andSMAD4 cause hered-
itary hemorrhagic telangiectasia, which are autosomal-dominant
disorders in which vascular malformations arise through the
formation of small-caliber vessel arterio-venous anastomoses
(Berg et al., 1997; Gallione et al., 2004; McAllister et al., 1994).
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TGFb signaling, thereby leading to vascular defects, including
inappropriate formation of a mural cell coat. This includes con-
nexins (Cx) 43 and 45, implicating the importance of gap junc-
tions for TGFb signaling in vascular development (Hirschi et al.,
2003; Kru¨ger et al., 2000). Studies on Cx43-deficient mesen-
chymal cells indicate that these cells had lost their ability to
produce active TGFb when cocultured with endothelial cells
and as a result failed to differentiate into a mural cell phenotype.
Likewise, several studies implicate integrins as critical regulators
of TGFb activation (Cambier et al., 2005). The role of integrins in
this process may involve the recruitment of MMPs to activate
latent TGFb (Cambier et al., 2005) or the direct liberation of active
TGFb through conformational changes of the latent TGFb com-
plex (Wipff and Hinz, 2008), a process recently proposed to in-
volve cell constriction-mediated tensile force across pro-TGFb
(Shi et al., 2011). Knockout of the orphan G protein-coupled
receptor gene grp124 in mice causes defective cerebral angio-
genesis and hemorrhage (Anderson et al., 2011; Cullen et al.,
2011; Kuhnert et al., 2010). TGFbwas demonstrated to stimulate
GPR124 expression, and molecular profiling of the gpr124
knockout vasculature revealed perturbed TGFb pathway activa-
tion, together suggesting a close crosstalk between GPR124
and TGFb (Anderson et al., 2011).
TGFb pathway proteins also interact with other key vascular
signaling pathways. Brain endothelium-specific knockout of
smad4 was recently shown to result in brain vascular defects,
involving increased endothelial proliferation, vascular dilation,
and reduced mural cell coverage (Li et al., 2011). This was con-
nected to reduced vascular expression of N-cadherin, a cell
adhesion molecule believed to mediate heterotypic cell contacts
between endothelial cells and pericytes (Gerhardt and Betsholtz,
2003; Gerhardt et al., 2000). It was further demonstrated that
TGFb and Notch signaling in endothelial cells cooperate in the
regulation of N-cadherin expression through direct interactions
of their transcriptional effectors on the N-cadherin promoter (Li
et al., 2011). Interestingly other signaling pathways may also
converge at the regulation of vascular N-cadherin. Binding of
plasma-borne bioactive lipid sphingosine-1-phosphate to the
endothelial-specific G protein-coupled receptor S1P1 (Edg1) is
critical for the mural cell recruitment to the developing dorsal
aorta and its proximal branches (Allende and Proia, 2002;
Allende et al., 2003; Liu et al., 2000). Possibly, this effect is medi-
ated by altered trafficking of endothelial cadherins VE- and
N-cadherin (Lee et al., 1999; Paik et al., 2004). Thus, several sig-
naling pathways known to be important for vascular maturation
(TGFb, Notch, and S1P) appear to regulate N-cadherin in hetero-
typic cell interactions between endothelial cells and pericytes.
Angiopoietin-1/Tie-2
Angiopoietin-1 (Ang-1) is expressed by perivascular mesen-
chymal cells (Davis et al., 1996), including pericytes (Sundberg
et al., 2002), whereas its main receptor, Tie-2, is predominantly
expressed on endothelial cells (Dumont et al., 1993). Thus, the
suggested Ang-1/Tie-2 paracrine loop has reciprocal orientation
in comparison with PDGF-B/PDGFRb and has been proposed to
mediate endothelial maturation and stability (Falco´n et al., 2009;
Gaengel et al., 2009) and reduce vascular leakage (Thurston
et al., 1999). Tie-2 expression has also been demonstrated in
subtypes of monocytes and macrophages (De Palma et al.,2005) and on certain pericytes (Cai et al., 2008b), potentially
complicating the picture of cellular interactions.
Ang1 or tie2 null mice develop cardiovascular defects and die
in utero around midgestation (Dumont et al., 1994). Morpholog-
ical analyses of ang1 and tie2 null embryos have demonstrated
a lack of mural cells (Patan, 1998; Suri et al., 1996). In humans,
mutations of the TIE2 gene lead to venousmalformation, a condi-
tion involving focal loss of venous mural cells (Vikkula et al.,
1996). A role for Tie-2 in pericyte recruitment and/or mainte-
nance is also suggested by the effects of local overexpression
of the Tie-2 antagonist Ang-2 (potentially inhibiting Ang-1-medi-
ated vascular stabilization), which leads to pericyte loss
(Hammes et al., 2004).
How the mural cell defects arise in situations of ablated or in-
hibited Ang-1/Tie-2 signaling remains unclear, however. Anal-
ysis of mouse chimeras of normal and tie2 null cells showed
that pericytes were recruited to Tie-2-negative endothelium
(Jones et al., 2001). Also, mice carrying signaling-deficient
Tie-2 receptors showed pericyte recruitment to new vessels in
spite of defective cardiac, hematopoietic, and endothelial devel-
opment (Tachibana et al., 2005). Likewise, conditional knockout
of ang1 showed that this gene is not required for pericyte recruit-
ment (Jeansson et al., 2011).
Thus, whereas Ang-1 and Tie-2 do not seem to be directly
involved in pericyte recruitment, several publications support
to the notion that pericyte-derived Ang-1 has important roles in
blood vessel formation and/or stability. Ang-1 overexpression
or administration results in increased vascular branching and re-
modeling of an immature vessel plexus into a higher-order hier-
archical structure (Thurston et al., 2005; Uemura et al., 2002).
Ang-1 expression (in pericytes) was recently demonstrated to
be dependent on the chicken ovalbumin upstream promoter-
transcription factor II (COUP-TFII), and conditional ablation of
couptf2 in adult mice led to compromised neoangiogenesis in
tumors and matrigel plugs (Qin et al., 2010). In addition, Ang-1
expression from hematopoietic cells appears to have a critical
role in angiogenesis, pericyte recruitment, and vascular stabili-
zation, as demonstrated in aml1 and hematopoietic cell-specific
zeb2 transcription factor gene knockout mice (Goossens et al.,
2011; Takakura et al., 2000). A recent study demonstrated that
cardiac-specific ang1 deletion reproduced the full knockout
phenotype and, moreover, that complete deletion after E13.5
was tolerated in the developing vasculature but produced de-
fects in situations of injury or vascular stress (Jeansson et al.,
2011). A tentative model consistent with most available data is
that Ang-1 produced by mesenchymal cells, including pericytes,
cardiomyocytes, hematopoietic cells, and possibly other cells
types, provides stabilizing signals to the endothelium that re-
duce vascular permeability and increase higher-order structure,
quiescence, and functionality of the vessel network during
cardiac development and in conjunction with vascular injury.
Other Signaling Pathways Implicated
in Endothelium-Pericyte Crosstalk
As discussed above, other signaling pathways than PDGF-B/
PDGFRb may exert a role as in mural cell recruitment in an
organ-specific or compensatory way. One such pathway is
heparin-binding epidermal growth factor (HB-EGF) signaling
through EGF receptors (ErbBs). Several studies indicate that
HB-EGF is essential for cardiovascular development (IwamotoDevelopmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 199
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to protect against the loss of pericytes from intestinal vessels
following mesenteric artery occlusion, possibly by induction of
pericyte proliferation and protection of the cells from oxidative
stress (Yu et al., 2010). The role of HB-EGF in mural cell biology
has been addressed mechanistically in vitro. In a cell coculture
model, HB-EGF expressed by endothelial cell was shown to
promote migration of vSMCs via ErbB1 and ErbB2 receptor
expression on vSMCs (Iivanainen et al., 2003). In this model,
HB-EGF expression on endothelial cells was enhanced by Ang-1,
suggesting that Ang-1 may promote pericyte recruitment
through HB-EGF. Analysis in more complex three-dimensional
in vitromodelsof angiogenesis inextracellularmatricesconfirmed
the importance of endothelium-derived HB-EGF and ErbB1 and
ErbB4 for pericyte recruitment (Stratman et al., 2010). Moreover,
the combined inhibition of PDGF-BB and HB-EGF in quail em-
bryos led to reduced pericyte recruitment and vascular pheno-
types reminiscent of those observed in mouse PDGF-B/PDGFRb
null embryos, suggesting that PDGF and EGF pathways may
collaborate in pericyte recruitment (Stratman et al., 2010). Addi-
tional support for a crosstalk between PDGF and EGF signaling
comes from studies of the ADAM17 protease, which releases
active HB-EGF from its transmembrane precursor (Sahin et al.,
2004). PDGFRb stimulates ADAM17 in cultured fibroblasts,
leading to proteolytic activation of EGFR ligands and stimulation
of EGFR signaling (Mendelson et al., 2010). ADAM17 is required
for vascular development and probably has a broad role in the
activation of substrates important for endothelial development
(Canault et al., 2010; Weskamp et al., 2010); however, it also
seems critical for mural cell recruitment (Canault et al., 2010).
Another pathway recently implicated in pericyte recruitment is
stromal-derived factor 1-a (SDF-1a)/CXCR4. SDF-1a promotes
pericyte migration in vitro and in a tumor xenograft model in vivo
(Song et al., 2009). Also for this signaling pathway a crosstalk
with PDGF-B/PDGFRb was suggested, since SDF-1a expres-
sion was shown to be stimulated by PDGF-B (Song et al.,
2009). Additional evidence for an involvement of a SDF-1a/
CXCR4 axis in pericyte recruitment was recently provided by
the demonstration in vitro that SDF-1a acts synergistically
together with hematopoietic cytokines SCF and IL-3 to mediate
endothelial tube formation and maturation, including pericyte
recruitment and vascular BM assembly (Stratman et al., 2011).
Analyses in mouse and avian embryos have demonstrated
a role for sonic hedgehog (Shh) signaling in vasculogenesis
(Vokes et al., 2004). Recent work also implicates Shh signaling
in pericyte recruitment in plexus choroideus formation (Nielsen
and Dymecki, 2010). The invading plexus choroideus pericytes
express theShh receptorPatched (Ptc), suggesting thatpericytes
are directly targeted by the Shh signal. The role of Shh/Ptc in
plexus choroideus formation resembles the role for PDGF-B/
PDGFRb in the development of glomerular pericytes (mesangial
cells) (Lindahl et al., 1998). Moreover, in both organs pericytes
appear to play a critical role in the formationof a specializedcapil-
lary network dedicated for plasma filtration (in the formation of
primary urine and cerebrospinal fluid, respectively). A possible
role for Shh signaling in mural cell regeneration has been impli-
cated through the demonstration that a population of vSMC
progenitors present in the adventitial layer of the arterial wall is
absent in Shh null mice (Passman et al., 2008). Recent studies200 Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc.also implicate Shh signaling in the recruitment of ‘‘perivascular
support cells’’ in zebrafish embryos. Analyses of hedgehog (Hh)
inhibitor-treated and Hh pathway mutant fish embryos demon-
strated detachment of the support cells and brain hemorrhage
(Lamont et al., 2010). Reduced Ang-1 expression is a possible
mediator of the defects, suggesting interactions between the
Hh and Ang-1/Tie-2 signaling pathways. Although the identity of
the perivascular support cells and their relationship to mural cells
remain poorly defined in zebrafish, recent work implicates the
existence of mural cells in fish embryos (Santoro et al., 2009).
Notch signaling has major roles in endothelial cells and is crit-
ically required for arteriogenesis and angiogenic sprouting (re-
viewed in Chappell and Bautch, 2010; Sainson and Harris,
2008). Notch signaling also plays a role inmural cells and in endo-
thelial-mural interactions. NOTCH3 is mutated in the human
stroke and dementia syndrome CADASIL (cerebral autosomal-
dominant arteriopathy with subcortical infarcts and leukoence-
phalopathy), which involves focal degeneration of vSMCs (Joutel
et al., 1996; Ruchoux et al., 1995). Analyses of notch3 knockout
mice have revealed an abnormal maturation of arterial vSMCs,
which has been connected to reduced expression of a number
of arterial vSMC markers, including PDGFRb (Domenga et al.,
2004; Jin et al., 2008). Increased expression of Notch3 in mural
cells has also been shown to increase expression of certain
vSMC markers (Liu et al., 2009). A critical Notch ligand in this
context appears to be Jagged-1 (Jag-1) expressed on endothe-
lial cells and induced in pericytes as part of an autoregulatory
loop of Jag-1/Notch3 expression in these cells (Liu et al., 2009).
Analysis of angiogenesis in the retina suggests a role for Notch3
in mural cell recruitment and implicates Ang-2 expression by the
mural cells as a possible mediator of Notch3-induced vessel
maturation (Liu et al., 2010). How this works is unclear, since
other studies have implicated Ang-2 as a vessel-destabilizing
factor, promoting pericyte loss (Hammes et al., 2004). In sum-
mary, however, there is accumulating evidence for a role of
Jag-1 andNotch3 signaling in endothelial-mural cell interactions.
Ephrin-Eph receptor signaling plays major roles in endothelial
cells but has also been implicated in mural cell biology. A mural
cell-specific knockout of ephrin-B2 resulted in poor association
of vSMCs and pericytes with vessels of different sizes (Foo et al.,
2006). In capillaries, pericytes made only loose connections with
the endothelial cells and were surrounded by abnormal extracel-
lular matrix deposits. How Ephrin-B2 in mural cells acts to
generate these defects is not fully clear. Eph receptor engage-
ment in endothelial cells andmural cells may play a role (Salvucci
et al., 2009), but migration defects in single Ephrin-B2-deficient
mural cells in vitro point to important cell-autonomous functions
of Ephrin-B2 in mural cells connected to the formation of focal
adhesions (Foo et al., 2006). Interestingly, ablation of the focal
adhesion protein a-parvin was recently demonstrated to lead
to contraction or migration defects in mural cells and a defective
mural cells association to vessels resembling the phenotype of
mural cell-specific ephrinb2 knockouts (Montanez et al., 2009).
Physiological Functions of Pericytes
Role of Pericytes and Brain Vascular Permeability
and the Formation of the Blood-Brain Barrier
An abnormally increased vascular permeability is associated
with many severe pathological conditions, including sepsis,
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Figure 5. Pericytes at the Blood-Brain Barrier
(A) Traits of the mammalian BBB controlled by pericytes. The circle depicts
four main traits of brain endothelium that collectively shield brain tissue: cell-
cell junctions, SLC-transporters, low rate of transcytosis, and ABC trans-
porters. The tightly sealed junctions restrict paracellular diffusion of most
blood-borne substances. Transporters (SLC and ABC) mediate influx of
essential polar molecules and efflux of xenobiotics. Transcytosis (adsorptive-
or receptor-mediated) mediates selective passage of proteins. The traits
develop at separate developmental stages depicted as bended arrows
(E, embryo; A, adult), where gray color indicates relative immaturity and red
relative maturity. The CNS pericytes are important for establishing the low
transcytosis rate of brain endothelial cell, as indicated by a blue arrow. In
addition, pericytes regulate the architecture of endothelial cell-cell, and
possibly also the expression of ABC transporters.
(B) Cellular components of the neurovascular unit. Presented is a schematic
cross-section of a brain capillary. The abluminal side of endothelium (E, blue) is
faced by a pericyte (P, pink) with which it shares BM (light brown). The entire
abluminal side of the vessel basement membrane is surrounded by astrocyte
endfeet (AEF, green). The endothelial and/or pericyte surface is contacted by
resident microglia (M, violet) and nerve endings (NE, red).
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Dudek, 2009). The normal capillary bed also differs in its perme-
ability in an organ-specific fashion. This primarily reflects differ-
ences in the specific characteristics of the endothelial cells. The
vasculature of the CNS possesses characteristics that result in
an ‘‘extreme’’ tightness of the vascular bed—the blood-brain
barrier (BBB)—which is a functional term denoting that the
healthy CNS vasculature is impermeable to the passive trans-
port of cells, proteins, and bioactive compounds present in the
blood. The BBB is a multicomponent system, the molecular
and structural complexity of which has only recently become
appreciated (reviewed in Abbott et al., 2010; Zlokovic, 2008)
(Figure 5).
Recent work has uncovered a critical role for pericytes in the
maturation and maintenance of the BBB (Armulik et al., 2010;
Bell et al., 2010; Daneman et al., 2010). The brain vessels thus
appear to harbor specialized pericytes, or alternatively they
respond topericyte signalsdifferently compared toother vessels.
Although pericyte diversity is still rather unexplored territory,
there are already indications that certain pericyte markers may
be brain specific (Bondjers et al., 2006; Heglind et al., 2005). As
discussed above, the CNS vasculature shows the highest peri-
cyte coverage among all analyzed organs. In addition, the brain
vasculature is 100% covered by glial cell processes formed by
astrocytes (astrocyte endfeet). The term neurovascular unit
(NVU) is often used to denote the CNS vasculature and its struc-
tural and functional connections to the neural tissue. Besides
endothelial cells, pericytes, and astrocyte endfeet, the NVU
includes microglia and neurons, which both contact blood
vessels by fine cytoplasmic processes (Figure 5). Therefore,
when the CNS vasculature is studied, the cellular and molecular
complexity of vessel-tissue interface needs to be taken intoaccount. Currently used in vitro models of brain vasculature do
not recapitulate the NVU complexity in vivo.
When and how do pericytes come into play in BBB develop-
ment? Previous review literature discusses the idea that peri-
cytes regulate the BBB at the level of endothelial junctions
(Abbott et al., 2010, 2006; Cardoso et al., 2010; Lai and Kuo,
2005). This conclusion is based on in vitro coculture studies
where pericytes were shown to increase the transendothelial
electrical resistance (TEER) of endothelial cell monolayers
(Al Ahmad et al., 2009; Dohgu et al., 2005; Hayashi et al., 2004;
Hori et al., 2004; Nakagawa et al., 2009). To what extent TEER
in vitro reflects the tightness of brain endothelial junctions and
the BBB in vivo is unclear, however, as lung pericytes increase
TEER in endothelial cultures as well (Dente et al., 2001). In addi-
tion, conflicting results on the effects of pericytes on TEER have
been reported (Zozulya et al., 2008). The majority of published
studies on the BBB are focused on the endothelial junctions,
which are a critical but not the only endothelial component of
the BBB. Additionally, brain endothelial transcytosis is sup-
pressed (reviewed in Smith and Gumbleton, 2006). This has
been documented, yet without an understanding of how this
process is regulated and when during the development it is
downregulated.
Two recent studies addressing the role of pericytes in the brain
vasculature challenge the ‘‘in vitro view’’ of pericytes regulating
the permeability of endothelial cell-cell junctions (Armulik et al.,
2010; Daneman et al., 2010). These studies were performed on
mouse models deficient in pericytes through genetic manipula-
tion of the PDGF-B/PDGFRb signaling pathway (see above).
One of the studies, performed in a neurobiology lab (Daneman
et al., 2010), asked which cell types are important for the devel-
opment of the BBB during embryogenesis. The other study was
performed in a vascular biology lab (Armulik et al., 2010) and ad-
dressed the function of pericytes in the adult mouse. Both
studies independently concluded that pericyte deficiency
caused increased brain vessel permeability, the extent of which
correlated directly with the density of brain pericytes. They also
found, somewhat unexpectedly, that the basis for the increased
permeability was upregulated endothelial transcytosis (Figure 6).
Finally, both studies demonstrated that the absence of pericytes
did not result in a general loss of the brain endothelial molecular
signature.
Currently it is unknown what type of endothelial transcytosis
and which molecular pathway(s) are deregulated in the peri-
cyte-deficient brain vessels. Microarray analysis of pericyte-
deficient blood vessels identified several deregulated genes
previously implicated in the regulation of endothelial perme-
ability, including vegfa, ang2, and adrenomedullin (all up in the
pericyte-deficient state) and ang1 (down in the pericyte-deficient
state) (Armulik et al., 2010; Daneman et al., 2010). The expres-
sion levels of ang1, ang2, and vegfa are consistent with the
increased vascular permeability. Adrenomedullin, on the other
hand, has well-documented protective effects on endothelial
barrier function in several organs (reviewed in Temmesfeld-Woll-
bru¨ck et al., 2007), and its strong upregulation in the pericyte-
deficient state may reflect a compensatory mechanism. All of
the abovementioned signaling molecules have been reported
to regulate permeability by modulating endothelial cell-cell
junctions; only VEGF has been connected to increasedDevelopmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 201
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Figure 6. Changes at the NVU in the
Pericyte-Deficient State
In the absence of pericytes (P, orange), the
endothelium (E, green) shows convoluted junc-
tions (J) and increased endothelial macro-
vesicular uptake (red vesicles; black arrowheads)
and release their content to brain parenchyma
(red arrowheads). Pericyte-deficiency affects
polarization of astrocyte endfeet (AF, blue),
shown by mislocalization of aquaporin-4 (Aqp4,
red) and altered deposition of astrocyte-derived
BM (aBM, dark brown). Deposition of endothe-
lium-derived BM (eBM, light brown) is not
affected in pericyte deficiency. Upregulation of
leukocyte adhesion molecules (only ICAM-1 is
depicted) on endothelium causes increased attachment of leukocytes (L, dark blue) in the lumen of pericyte-deficient blood vessels. The release of intra-
venously administered tracers into the brain parenchyma is inhibited by Imatinib treatment. Adapted from Armulik et al. (2010).
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tubular organelles (reviewed in Mehta and Malik, 2006). In
general, the regulation of endothelial permeability is complex
and dissection of the role of each candidate protein in peri-
cyte-deficient mice will require further work.
Absence of brain pericytes seems to upregulate a transcytosis
pathway that does not discriminate between different types of
molecules and sizes (Armulik et al., 2010). In addition, the peri-
cyte-deficient animals demonstrated defects in the polarization
of astrocyte endfeet (Armulik et al., 2010), indicating that peri-
cytes influence the development of the NVU at multiple levels.
The treatment of pericyte-deficient mice with the drug Imatinib
halted the extravasation of tracers without correcting pericyte
coverage or astrocyte polarization defects. The administred
tracers accumulated in endothelial vesicles, however, indica-
ting that Imatinib blocked the endothelial release (exocytosis),
not uptake (endocytosis), of the tracers (Armulik et al., 2010)
(Figure 6). The specific target of the Imatinib involved in this
process is currently unknown. Imatinib is a tyrosine kinase inhib-
itor with broad substrate specificity and several reported off-
target effects (Cataldi et al., 2004; He et al., 2010; Netzer et al.,
2003).
Interestingly, increased endothelial transcytosis has been
reported to occur during several pathological conditions (re-
viewed in Nag et al., 2011). There are reports indicating that early
BBB damage is associated with increased transcytosis, whereas
the loss of endothelial junctional integrity takes place later (Nag
et al., 2011). Coincidentally, pericytes have been described to
leave the vessel wall during several pathological conditions
(e.g., tumors, trauma, sepsis, diabetic microangiopathy, and
fibrosis (further discussed below). The pathogenic significance
of pericyte dropout from the vessel wall is currently unknown
but one might speculate on a role in increased endothelial
permeability. Recent work also suggests that progressive peri-
cyte loss in the brain and subsequent increase of vessel perme-
ability may promote neurodegeneration in aging mice (Bell et al.,
2010).
Do Pericytes Regulate Blood Flow?
Capillary constriction, the first function suggested for pericytes,
was largely based on indirect evidence (reviewed in Dı´az-Flores
et al., 2009; Hamilton et al., 2010; Puro, 2007). As imaging tech-
niques have evolved, pericyte-mediated capillary constriction in
response to vasoactive substances and neurotransmitters has
been observed in some situations in vivo and in organ cultures202 Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc.ex vivo. For a detailed description of molecular pathways
engaged in response to vasoactive molecules and neurotrans-
mitters in a ‘‘generic’’ pericyte, leading to capillary constriction
or dilation, the reader is referred to recent review articles on
the topic (Attwell et al., 2010; Hamilton et al., 2010).
What is the physiological relevance of pericyte contractility? In
the brain, the regional blood flow increases in response to
increased local neuronal activity. This process, called functional
hyperemia, is neurotransmitter mediated and occurs at the level
of arterioles (reviewed in Attwell et al., 2010). The demonstration
of pericyte-mediated constriction of capillaries ex vivo in cere-
bellar brain slices and retina preparations may suggest capil-
lary-mediated control of blood flow in the CNS as well (Peppiatt
et al., 2006). A recent study demonstrated pericyte-dependent
capillary constriction in vivo using intravital microscopy (Ferna´n-
dez-Klett et al., 2010), however, without evidence for capillary-
mediated functional hyperemia. Another study used ex vivo
cerebral slices and in vivo imaging to suggest that pericyte con-
traction caused by oxidative stress after brain ischemia/reperfu-
sion leads to capillary constriction (Yemisci et al., 2009), indi-
cating that pericytes may regulate capillary blood flow in
pathological situations.
Although the aforementioned studies may seem to provide
evidence for pericyte contraction in blood flow regulation,
a number of caveats exist in interpreting the data. First, con-
vincing evidence for blood flow control elicited solely at the capil-
lary level in vivo is still lacking. Second, while the identification of
pericytes is problematic in fixed specimens due to the lack of
specific markers (discussed above), it is even more challenging
in living tissues. In a study of cochlear pericytes, the vasculature
was visualized by labeling with DAF-2DA, an intracellular
detector of NO (Dai et al., 2009), whereas pericytes were distin-
guished by the shape of their cell body. In the other studies, peri-
cytes were also identified by their cell body morphology in beta-
actin-GFP transgenic mice (Ferna´ndez-Klett et al., 2010), or
without any labeling (Peppiatt et al., 2006; Yemisci et al.,
2009). This raised concerns about the proper identification of
pericytes and the type of microvessels studied (Vates et al.,
2010). Third, it is unclear whether the long slender pericyte pro-
cesses may generate enough force to constrict a capillary.
Finally, different results have been recorded in the same organ
in vivo and ex vivo (Dai et al., 2009). Clearly, the jury is still out
concerning pericyte contraction and the regulation of blood
flow in physiological and pathophysiological situations.
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in Tissue Regeneration?
A number of recent studies suggest that pericytes may consti-
tute multipotent stem and/or progenitor cells, such as mesen-
chymal stem cells (MSCs) (Crisan et al., 2008b; Davidoff et al.,
2004; Feng et al., 2011), white adipocyte progenitors (Olson
and Soriano, 2011; Tang et al., 2008), muscle stem cells (Della-
valle et al., 2007), and even neural stem cells (Dore-Duffy et al.,
2006). To discuss this issue, we need to go back 40 years,
when MSCs were identified as fibroblast-like cells, called
CFU-F (colony- forming unit fibroblastic) in human bone marrow
cell cultures seeded at clonal density (Friedenstein et al., 1970).
When heterotopically transplanted, these single-cell-derived
clones generated cartilage, bone, adipose, and fibrous tissue.
The cells were later named bone marrow mesenchymal stem
cells (BM-MSCs), whereas cells with similar lineage potential
for in vitro differentiation (adipocyte, osteoblast, chondrocyte)
subsequently identified in other tissues were referred to as
MSCs. The easy access to MSCs provides prospects for human
regenerativemedicine, but the identity and function of these cells
in vivo remain unclear. Do MSCs strictly fulfill the criteria of
a stem cell, i.e., do they self-renew, and can their progeny differ-
entiate into a functional multiple cell types of a given tissue? The
reader is referred to recent excellent reviews that discuss this
topic (Garcı´a-Go´mez et al., 2010; Nombela-Arrieta et al., 2011).
Nearly ten years ago it was shown that MSCs reside in
a vascular niche in bone marrow and dental pulp (Shi and Gron-
thos, 2003). Simultaneously, cultured pericytes were shown to
differentiate in vitro into osteoblasts, adipocytes, chondrocytes,
vSMCs, and skeletal muscle (Collett et al., 2003; Dellavalle et al.,
2007; Doherty et al., 1998; Farrington-Rock et al., 2004).
Together, these observations paved the way for the concept
of a perivascular niche for MSCs (reviewed in Corselli et al.,
2010). Recent work has extended this concept to several other
tissues in addition to bone marrow and dental pulp and provided
further support for the notion that that MSCs derive from peri-
cytes (Crisan et al., 2008a; Crisan et al., 2008b). However,
whereas there is no doubt that MSCs can be isolated from peri-
vascular locations in most—perhaps all—organs (Crisan et al.,
2008b; Dellavalle et al., 2007; Tang et al., 2008), the question
remains whether they are identical to the cells that a vascular
biologist would refer to as pericytes. Usually, conclusions are
based on a small number of pericyte markers, such as NG2
and PDGFRb, which somtimes occur in combination with endo-
thelial markers, such as CD105 and CD34 (Corselli et al., 2010;
Galvez et al., 2008). A detailed discussion about the marker
expression in MSCs and pericytes has been reviewed elsewhere
(Anjos-Afonso and Bonnet, 2011). For example, PDGFRb was
used as a marker to demonstrate a mural cell origin of white
adipocytes (Tang et al., 2008) andmuscle progenitors (Dellavalle
et al., 2007). Consitutive activation of PDGFRb by targetedmuta-
genesis of the endogenous gene inhibited adipogenesis, de-
monstrating the involvement of this pericyte marker protein in
adipocyte differentiation (Olson and Soriano, 2011). However,
as discussed above, PDGFRb is also expressed by certain fibro-
blasts (Andrae et al., 2008; Heldin and Westermark, 1999), and it
is therefore still not entirely clear whether perivascular mesen-
chymal stem or progenitor cells expressing PDGFRb derive
from pericytes proper, or from, e.g., perivascular fibroblasts.The adventitial layer of larger vessels has been demonstrated
to contain stem cells that have the capacity to generate vSMCs
(reviewed in Ergu¨n et al., 2011; Hoglund et al., 2010). Moreover,
in cases where cells have been sorted by FACS from blood
vessels, the vascular preparations have included vessels of
different caliber and type (i.e., not only pericyte-containing
microvessels), and rigorous analyses on the homogeneity of the
isolated cell population have not been performed. Finally, even
if some pericytes may possess plasticity, it is unsolved whether
all pericytes have the same stem or progenitor cell potential.
The lack of absolutely specific genetic tools for pericyte
labeling limits interpretation of cell sorting data but also the pros-
pects for conclusive fate mapping. A few studies have neverthe-
less been performed using pericyte-expressed Cre recombi-
nase. Pdgfrb-Cre was used to trace white adipocytes to a
mural cell origin, but as already underlined, PDGFRb is ex-
pressed by other mesenchymal cell types as well. A recent study
made use of ng2-Cre and tamoxifen-inducible ng2-CreER mice
to address the ability of pericytes to generate odontoblasts
(Feng et al., 2011). NG2 is also not a completely specific pericyte
marker (Table 1), hence, ng2-Cremice need to be further charac-
terized before it can be concluded to what extent their Cre
expression is restricted to (and efficient in) pericytes in different
organs.
Some reports suggest that pericytesmay have a broader plas-
ticity than the classical MSC repertoire of fates. One such
example is the testosterone-producing Leydig cells present in
the testis mesenchyme. Pericytes have been proposed to act
as a progenitor pool for the regeneration of Leydig cells following
their experimental elimination (Davidoff et al., 2004). The new
Leydig cells appeared close to vessels, and it was therefore
concluded that the progenitor cells are vSMCs and/or pericytes.
However, the perivascular Leydig cell progenitors expressed the
neural/glial marker nestin, raising some doubt as to their identity.
Leydig cells have been proposed to derive from PDGFRa-posi-
tive mesenchymal cells residing in the testis mesenchyme at
perivascular locations (Gnessi et al., 2000). A more surprising
finding, perhaps, is that CNS pericytes are able to generate
self-renewing spheres in vitro with the capacity to differentiate
into neural cell lineages (Dore-Duffy et al., 2006). Similar to other
studies, however, the lack of defining pericytes markers compli-
cates the interpretation also of this study. The purification of peri-
cytes from isolated brain microvessels was based on markers
(NG2 and nestin) also expressed on neural progenitor cells
(Aguirre et al., 2004; Belachew et al., 2003; Lendahl et al.,
1990). There is also strong evidence that neural stem cells reside
in a perivascular niche (Tavazoie et al., 2008). Together with the
issues of marker specificities, this raises doubt concerning the
pericyte origin of the plastic neural cells residing in the vascular
niche. On a more general note, this is also relevant for the inter-
pretation of in vitro data on cultured pericytes, since these are
usually derived from vascular preparations using counterselec-
tion for endothelial cells. Currently, therefore, the origin of both
MSC and pericyte cultures remains unclear in most instances.
A growing number of studies nevertheless demonstrate that
tissue resident stem cells reside in vascular niches, including
neural, hematopoietic, and mesenchymal stem cells (Tavazoie
et al., 2008, and reviewed in Corselli et al., 2010; Ehninger
and Trumpp, 2011; Ergu¨n et al., 2011). During embryonicDevelopmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 203
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Figure 7. Hypothetic Roles of Pericytes in
Pathology
During pathophysiological processes (inflamma-
tion, fibrosis, tumor growth), pericytes are acti-
vated by a combination of growth factors. In con-
junction with fibrosis, pericytes display changed
marker profiles (indicated in speech balloons),
detachment from the BM, and transdifferentiation
into myofibroblasts (dashed arrow). Detachment
of pericytes causes increased vessel permeability
(bended arrow). Myofibroblasts deposit collage-
nous extracellular matrix. In tumors, tumor peri-
cytes exhibit altered marker expression (indicated
in speech balloons), and modulate trafficking of
inflammatory cells, tumor growth and metastasis
(arrows), endothelial cell normalization, and vas-
cular permeability (bended arrow). The extent of
pericyte-mediated modulation of inflammatory
cells in fibrosis, and pericyte transdifferentiation
into fibroblasts or myofibroblasts in cancer, is
proposed by many studies but is still largely
unclear (indicated by ‘‘?’’).
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have a role in tissue induction that goes beyond the simple
supply of nutrients and oxygen (Lammert et al., 2001; Matsu-
moto et al., 2001). It is perhaps therefore not surprising that the
adult vasculature harbors stem cells that are actively involved
also in tissue repair. Recent studies on liver regeneration indicate
the active role of liver endothelial cells and hepatic stellate cells
in hepatocyte proliferation (Ding et al., 2010; Passino et al.,
2007). During the healing of bone fractures, the invading vascu-
lature was shown to be closely associated with osteoblasts
(Maes et al., 2010). Also, human skin pericytes have been shown
to enhance the regenerative capacity of human dermis in cocul-
ture models by expression of laminin a5 chain, a protein that has
been shown to promote skin regeneration (Paquet-Fifield et al.,
2009).
Pathological Roles of Pericytes
Are Pericytes a Fibrosis-Generating Cell Type?
Fibrosis is a common pathophysiological response of many
tissues to chronic injury. Wound healing and tissue remodeling
and repair are processes normally activated in response to injury
to maintain the original architecture and integrity of tissues and
organs. However, prolonged exposure to the chronic injurious
stimuli causes deregulation of normal processes and result in
an excess deposition of extracellular matrix, scar formation,
and organ failure (reviewed in Kisseleva and Brenner, 2008).
Fibrosis is caused by a cascade of events, including damage
to the epithelium or endothelium, release of TGFb1, recruitment
of inflammatory cells, and activation of myofibroblasts as
collagen-producing cells (Kisseleva and Brenner, 2008).
One of the critical steps in fibrosis progression is the activation
of myofibroblast progenitors. Myofibroblasts are fibroblast-like
cells that express aSMA, deposit pathological extracellular
matrix, and are directly responsible for the extent of fibrosis.
Identifying the origin of the myofibroblasts constitutes a chal-204 Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc.lenge (Hinz, 2007). Currently, there are
several hypotheses about the cellular
origin of myofibroblasts, including resi-
dent fibroblasts, fibrocytes, epithelialcells (following EMT), bone marrow-derived cells, endothelial
cells (following endothelial-to-mesenchymal transition), and
pericytes (reviewed in Powell et al., 2011; Varga and Trojanow-
ska, 2008).
The role of pericytes asmyofibroblast precursors is suggested
by studies of fibrogenesis in the liver (Fabris and Strazzabosco,
2011), kidney (Schrimpf and Duffield, 2011), and systemic scle-
rosis (SSc) (Mahoney et al., 2011; Wei et al., 2011). Recent
studies have used genetic fate mapping to address the origin
of myofibroblasts in fibrosis. While these studies excluded
epithelial cells undergoing EMT as the fibrogenic cell population
in liver fibrosis (Scholten et al., 2010), FoxD1-Cremicewere used
to identify interstitial mesenchymal cells as the myofibroblast
precursors in the kidney. These cells expressed PDGFRb and
CD73, prompting the suggestion that they may be pericytes
(Duffield and Humphreys, 2011; Lin et al., 2008). Whereas
PDGFRb is an accepted pericyte marker, CD73 is reportedly ex-
pressed on leukocytes and endothelial cells (Stagg et al., 2011),
however, raising some doubt about the conclusions. In
summary, while the origin of myofibroblasts is far from being
elucidated, accumulating evidence indicates that pericytes
may constitute a source of myofibroblast progenitors (Figure 7).
Pericytes in Cancer Biology
Pericytes: an obligatory component of the tumor stroma. Tumors
are not only composed of malignant cells. Neoplastic cells
coexist with a variety of extracellular matrix components and
cell types such as fibroblasts, myofibroblasts, endothelial cells,
pericytes, and leukocytes. Together, these components, termed
tumor stroma, build up the microenvironment in which the
cancer cells proliferate. As tumors progress, the stromal
compartment evolves through continuous paracrine interaction
between the tumor cells and stroma cells, and among the
different types of stroma cells themselves. It is now acknowl-
edged that the tumor stroma is an essential component of tumor
growth, invasiveness, and promotion of tumor dissemination
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the important functions of the stroma in tumor initiation, growth,
and progression has led to the notion that the tumor microenvi-
ronment influences the therapeutic outcome, as well as provides
opportunities for therapeutic targeting (reviewed by Pietras and
Ostman, 2010).
Pericytes are a ubiquitous part of the tumor microenvironment
(reviewed by Hanahan and Weinberg, 2011). Yet, in contrast to
other tumor stroma cellular components, little is known about
their recruitment, identification, and interaction with other
stromal or tumor cells. Whereas targeting endothelial cells or
cancer-associated fibroblasts might represent a therapeutic
advantage (Pietras and Ostman, 2010), concomitant targeting
of pericytes has unclear therapeutic effects (Hainsworth et al.,
2005; Nisancioglu et al., 2010). In this chapter, we review the
current understanding of tumor pericyte origin, recruitment,
and functions, as well as discuss emerging areas in tumor peri-
cyte research. Finally, we summarize our present understanding
about hemangiopericytomas as tumors arising from pericytes.
Recruitment of pericytes to tumor vessels. As it occurs during
physiological angiogenesis, pericytes are recruited into tumor
blood vessels by PDGF-B/PDGFRb signaling (Abramsson
et al., 2002). In a mouse model of malignant melanoma, overex-
pression of PDGF-B by the tumor cells resulted in increased
recruitment of pericytes and stabilization of the tumor neovascu-
lature (Furuhashi et al., 2004). Tumors grown in pdgfbret/ret mice
show fewer pericytes in the tumor vasculature, as well as
increased detachment of the fewer pericytes present (Abrams-
son et al., 2003; Nisancioglu et al., 2010). Interestingly, the
amount of pericytes but not their proper attachment to the tumor
blood vessels could be partially rescued when tumor cells were
engineered to express PDGF-B (Abramsson et al., 2003), sug-
gesting that an endothelial source of PDGF-B is important for
the proper pericyte investment of tumor blood vessels.
Recent reports suggest a role for HB-EGF in the recruitment of
pericytes to the tumor vasculature in a model of pancreatic
cancer (Nolan-Stevaux et al., 2010) and of pericyte-expressed
EGFR in the development of resistance of antiangiogenic therapy
in a xenograft model of lung carcinoma (Cascone et al., 2011).
Another study reports that SDF-1a may recruit tumor pericytes
via CXCR4 (Song et al., 2009). These studies thus provide
grounds to assume that other factors than PDGF-B might be
directly involved in pericyte recruitment to the tumor vasculature.
When three different tumor models were grown subcutaneously
in the pericyte-deficient pdgfbret/ret mice the reduction in peri-
cytes observed was different for every tumor model studied
(Nisancioglu et al., 2010), suggesting tumor-type-specific
involvement of multiple pathways in pericyte recruitment.
What is the origin of tumor pericytes? Coinjection of mouse
embryonic fibroblasts from XlacZ4 mice with tumor cells into
a subcutaneous space resulted in recruitment of LacZ+ cells
exclusively to perivascular locations in the tumors, suggesting
that pericytes may be recruited from local immature mesen-
chymal cells (Abramsson et al., 2002). Transplantation of GFP+
bone marrow into irradiated mice led to GFP+ cell accumulation
in perivascular locations in a variety of tumor models (Du et al.,
2008; Rajantie et al., 2004). This process appeared to be depen-
dent at least in part on SDF-1a expression (Song et al., 2005).
Although located perivascularly, these NG2-positive cellsexpressed additional monocyte markers, such as CD45 or
CD11b. Thus, whether these cells are indeed pericytes, or peri-
vascular fibroblasts or infiltrating monocytes, remains uncertain.
Whereas pericytes are attracted to the tumor neovasculature
by the same means as in developmental angiogenesis, pericyte
investment of tumor blood vessels is clearly aberrant (Morikawa
et al., 2002). The extent of pericyte coverage on tumor vessels is
typically diminished as compared to normal tissues, and peri-
cytes are loosely associated to the endothelial cells, with cyto-
plasmic processes that penetrate deep in the tumor paren-
chyma. The exact causes of the abnormal pericyte behavior in
tumors are still unknown. Tumor hypoxia drives VEGF-A expres-
sion, and while VEGF-A is a potent mediator of endothelial
sprouting and neovascularization, it is not efficient in generating
a mature vascular network (Chen et al., 2007). Also, VEGF-A has
recently been shown to be a negative regulator of pericyte func-
tion and vessel maturation (Greenberg et al., 2008). Thus,
hypoxia-triggered proangiogenic factors might impair pericyte
recruitment and investment of the tumor vasculature by keeping
pericytes in an ‘‘activated’’ state (Raza et al., 2010).
Identification of pericytes in tumors is associated with the
same concerns as during normal development. As mentioned
earlier, tumor pericytes are loosely associated with endothelial
cells, complicating identification of pericytes according to mor-
phological criteria. Electron microscopy shows partial detach-
ment of tumor pericytes (Baluk et al., 2005). Commonly used
immunohistochemical markers for tumor pericytes include
aSMA (Nisancioglu et al., 2010; Ozawa et al., 2005; Sennino
et al., 2007), NG2 (Abramsson et al., 2003), PDGFRb (Ozawa
et al., 2005), desmin (Sennino et al., 2007), RGS5 (Berger et al.,
2005; Nisancioglu et al., 2008), and the XlacZ4 transgenic mouse
(Abramsson et al., 2002) (Figure 7). ASMA is often absent in
quiescent pericytes in normal tissues (Table 1), notably in the
CNS. However, aSMA is readily detected in pericytes in patho-
logical conditions such as tumor angiogenesis, tissue fibrosis,
and inflammation (Gerhardt and Betsholtz, 2003). TGFb, which
has been involved in smoothmuscle cellmaturation, is a potential
driver of the expression of aSMA in tumor pericytes (Song et al.,
2005).
Tumor pericytes as therapeutic targets. The tumor stroma
influences the outcome of therapeutic approaches and may
hence provide targets for therapeutical intervention (Pietras
and Ostman, 2010). Recent analysis of the causes of resistance
to anti-VEGF therapy points to an important role of tumor-infil-
trating leukocytes in providing other angiogenic signals (Casa-
novas, 2011; Shojaei and Ferrara, 2008). Pericytes have also
been proposed to protect the endothelium in situations of
VEGF-A inhibition. VEGF-A ablation in tumors led to selective
elimination of tumor blood vessels that lacked pericyte coverage
(Benjamin et al., 1999). Double targeting of both endothelial cells
and pericytes has been suggested to have better antitumoral
effect than targeting of any of the cell types alone (Bergers
et al., 2003; Erber et al., 2004). However, the pharmacological
approaches used involved tyrosine kinase inhibitors, which are
known for their promiscuity regarding molecular targets (Fabian
et al., 2005). Thus, the enhanced antitumor effect observed may
reflect inhibition of other signaling pathways than those in-
tended. The approach for double targeting of endothelial cells
and pericytes used in preclinical studies has also been testedDevelopmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 205
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2007). Also, other work in preclinical models has failed to demon-
strate increased effects of endothelial targeting in the absence of
pericytes (Nisancioglu et al., 2010). Depletion of pericytes
instead led to an unexpected increase in tumor growth in some
models (Nisancioglu et al., 2010; Sennino et al., 2007). A correla-
tion between poor pericyte coverage of tumor vasculature with
increased metastatic events has also been reported (discussed
below). In summary, the question whether targeting tumor peri-
cytes is of therapeutic advantage is still unanswered.
Pericytes and tumor vessel normalization. In contrast to the
healthy tissue vasculature, tumor vessels are highly abnormal
structurally and functionally (Jain, 2005). Apart from aberrant
pericyte coverage, tumor vessels are characterized by irregular
shape and a disorganized architecture with highly dysfunctional
and leaky endothelial cell layers. All these changes harm tumor
perfusion, resulting in poor drug access to the tumor and
impaired oxygen delivery. Together, the aberrant features of
tumor blood vessels have been recently considered a hallmark
of cancer (De Bock et al., 2011). The abnormal features are the
consequence of persistent production of proangiogenic factors,
notably VEGF-A.
Pharmacological blockade of VEGF-A signaling reverts—
albeit transiently (Winkler et al., 2004)—the aberrant features of
tumor vasculature, leading to vessel normalization. Tumor
vessels thereby resemble the vessels of normal tissues, resulting
in improved oxygen, drug, and nutrient delivery to the tumor
(Jain, 2005). Of importance for this discussion is that the vessel
normalization correlates with increased pericyte coverage and
attachment to the vascular wall.
Tumor vessel normalization is desirable because it improves
drug and chemotherapy delivery to the tumor. Because normal-
ization appears to be a transient result of antiangiogenic therapy
(Winkler et al., 2004), it might be advantageous to increase its
duration, and hence we need to learn more about its mecha-
nisms. Does tumor vasculature normalize as a consequence of
improved pericyte abundance (and/or function) or does normal-
ization cause more efficient pericyte recruitment as a bystander
effect? A recent study provides some evidence that strengthens
the case of pericytes as regulators of vascular normalization.
Experimental pancreatic cancer grown in mice deficient for the
pericyte marker RGS5 showed increased pericyte maturation
and vascular normalization, which correlated with diminished
vessel leakiness and hypoxia (Hamzah et al., 2008).
Emerging Concepts in Tumor Pericyte
Research—Transendothelial Migration
of Tumor Cells and Leukocytes
The tumor microenvironment has a major role in modulating the
metastatic capacity of most cancers. Most of our knowledge on
stroma-promoting metastatic events comes from studies on
cancer-associated fibroblasts or infiltrating immune cells (Joyce
and Pollard, 2009; Pietras and Ostman, 2010). However, peri-
cytes may be involved as well (Gerhardt and Semb, 2008;
Raza et al., 2010). Evidence for the contribution of pericytes to
increased metastatic events comes from an experimental model
of pancreatic cancer (Xian et al., 2006) as well as from human
colorectal cancer patients (Yonenaga et al., 2005). An associa-
tion betweenmetastatic events and reduced expression ofmural
cell markers has been demonstrated across a wide range of206 Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc.human solid tumors, suggesting that low pericyte coverage
may trigger metastasis and correlate to poorer prognosis (Ram-
aswamy et al., 2003). Beyond these correlations, the question
about cellular and molecular mechanisms remains. It is still
unclear whether pericytes actively promotemetastasis or consti-
tute a physical barrier to vascular dissemination and/or extrava-
sation of tumor cells. The former has no plausible hypothesis as
of yet. The latter could be explained because pericyte deficiency
increases interstitial fluid pressure, which might promote a
passive flow of detached tumor cells into the circulation through
leaky endothelial cell layers. Moreover, pericytes could play
a role in limiting the colonization of metastatic tumor cells at
the site of extravasation. Metastasizing melanoma or lung carci-
noma cells gain access to the brain and then remain in perivas-
cular locations where they undergo apoptosis or grow into an es-
tablished metastasis (Kienast et al., 2010). Pericyte dysfunction
may hence alter the perivascular microenvironment facilitating
the colonization and growth of metastatic cells in the target
organ.
The transmigration of inflammatory cells to the site of inflam-
mation entails a complex cascade of events that involve the
inflammatory cells, cytokines, endothelial cells, BM, and peri-
cytes. This process is comprehensively reviewed elsewhere
(Nourshargh et al., 2010; Soehnlein and Lindbom, 2010). In brief,
there are several physical barriers that the inflammatory cells
must overcome in order to reach into the tumor or inflammatory
site, including the endothelium, the BM, and the pericytes. By
using in vivo imaging, recent studies suggest that inflammatory
cells migrate across the vessel wall at permissive sites devoid
of pericyte coverage (Voisin et al., 2010;Wang et al., 2006). Other
reports implicate pericytes in the regulation of T cell exit from the
thymus (Zachariah and Cyster, 2010) and in the regulation of
leukocyte adhesion molecules in endothelial cells (Daneman
et al., 2010) (discussed above). Recent findings suggest a role
for tumor pericytes in regulating the transmigration of inflamma-
tory cells. Tumors developed in mice deficient for the pericyte-
specific gene RGS5 showed increased infiltration of CD8+/
CD4+ T cells after adoptive transfer. These data suggest that
pericytes may modulate the vasculature to adapt to different
conditions, either facilitating or inhibiting the trafficking of im-
mune cells (Hamzah et al., 2008). It was also recently demon-
strated that PDGFRb activation leads to upregulated expression
of a battery of immune response genes in pericytes (Olson and
Soriano, 2011). Thus, immune modulation and transmigration
of inflammatory cells may be added to the growing list of pericyte
mediated vascular functions of relevance for the design of anti-
angiogenic and vascular targeting strategies in cancer and other
diseases (Figure 7).
Tumors Arising from Pericytes
Hemangiopericytomas (HPCs) were first described as tumors
arising from the pericytes described by Zimmermann (Stout
and Murray, 1942). HPCs primarily affect adults of 20–70 years
of age (Enzinger and Smith, 1976). The most commonly affected
anatomic sites for HPCs are lower extremities, retroperitoneum,
and head and neck, notably in the supratentorial meninges.
HPCs bear a close histomorphological similarity to solitary
fibrous tumors, which makes them often indistinguishable
(Gengler and Guillou, 2006; Park and Araujo, 2009). In fact,
in the WHO classification, the concept of HPC as a vascular,
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cell of origin (Fletcher, 2006).
Diagnosis of HPC is initially based on typical architectural
vascular pattern associated with a population of mesenchymal
cells that display no discernible differentiation under light micro-
scope (Koch et al., 2008). The vessels form a vascular network
with branching vessels of various diameters, with the smaller
vessels partly compressed by the surrounding cellular prolifera-
tion. On the immunohistochemistry level, HPCs express aSMA
and CD34, being negative for CD31, GFAP, and Mib-1. Under
these criteria, HPC is classified as WHO grade II (Louis et al.,
2007). Management of HPC is preferentially by surgical resec-
tion. It is notoriously difficult to predict the prognosis and clinical
behavior of HPC (Gengler and Guillou, 2006), perhaps because
at the pathology level it is difficult to define malignant character-
istics. Different studies report disparate incidence of metastasis
(10%–60%). Being a highly vascularized tumor, HPC has then
become a target for antiangiogenic therapies. Combined
therapy with Bevacizumab and temozolomide showed prom-
ising results (Park et al., 2011). Sorafenib and Sunitinib have
also been employed with relative success (Mulamalla et al.,
2008).
In summary, HPC is a rare mesenchymal tumor with unclear
cellular origin, presumably pericytes. Diagnosis, management,
and metastatic potential are ill defined, and despite some recent
therapeutic improvements by employing antiangiogenic drugs
(Park et al., 2010), a better understanding of the molecular path-
ogenesis of this malignancy is much needed.
Pericytes in Diabetic Retinopathy
Diabetic retinopathy is one of the most common complications
of diabetes, with one-third of adult diabetic patients affected,
and constitutes a leading cause of blindness (Cheung et al.,
2010). Together with diabetic nephropathy it is considered the
prototypical microvascular complication of diabetes. This view,
however, has been recently widened to include the entire array
of changes that occur during the disease (Gardner et al.,
2011). The microvascular changes manifest as pericyte death
and BM thickening with altered blood flow in the retina capil-
laries. These changes lead to capillary leakage—macular
edema—and vessel occlusion and constitute the nonprolifera-
tive phase of diabetic retinopathy. Proliferative diabetic retinop-
athy develops secondary to capillary occlusion, which upregu-
lates growth factors, notably VEGF-A. Proliferative retinopathy
is defined by the growth of abnormal new vessels from the retina
to the posterior surface of the vitreous or the iris.
It is currently accepted that diabetic retinopathy manifests
first by vascular cell apoptosis, including pericyte detachment,
thickening of the BM, vascular dysfunction, and permeability,
all traits of the nonproliferative phase of the disease. The pro-
tease technique (Bresnick et al., 1977) used for the study of
the retinal vasculature in fixed specimens consistently reveals
the presence of pericyte ‘‘ghosts,’’ or pockets in the BM
that appear to have harbored a pericyte (Kern et al., 2000).
Other studies noted the absence of pericytes in some capil-
laries with intact endothelial cells and that vessels with mi-
croaneurysms tended to have no pericytes (Barber et al.,
2011).
The cause of pericyte apoptosis in diabetic retinopathy is
poorly understood. Some possible mechanisms link pericyteapoptosis with increased oxidative stress and NF-kB activation
(Romeo et al., 2002). Disruption of the PDGF-B/PDGFRb
signaling axis has also been suggested to play a role in pericyte
apoptosis. Endothelial cell ablation or reduced levels of PDGF-B
have been shown to recapitulate the pericyte loss and aneu-
rysms and some of the vascular changes that characterize dia-
betic retinopathy (Enge et al., 2002; Hammes et al., 2002). Inter-
estingly, a recent study identified overexpression of PKCd in
pericytes following hyperglycemia. Activation of PKCd phos-
phorylates p38a MAPK, resulting in increased expression of
the tyrosine protein phosphatase SHP-1. This signaling cascade
leads to PDGFRb dephosphorylation and pericyte apoptosis
(Geraldes et al., 2009). It is unclear how hyperglycemia induces
PKCd overexpression.
Another of the key attributes of the nonproliferative phase of
diabetic retinopathy is the loss of blood-retinal barrier integrity
leading to increased permeability and macular edema, which in
turn precedes vascular proliferation (Ockrim and Yorston,
2010). Several cellular andmolecular mediators have been impli-
cated in the onset of macular edema, such as VEGF-A,
advanced glycation end products, or TGFb (Ehrlich et al.,
2010). Given the similarities between the blood-brain barrier
and the blood-retinal barrier, macular edema could be caused
by pericyte dropout leading to increased endothelial transcyto-
sis. Indeed, vesicular transport-related genes such as caveo-
lin-1 and PV-1 were demonstrated to be consistently upregu-
lated in the retinas of diabetic rats, whereas genes encoding
for tight junctions such as occudin and claudin-5 showed only
marginal downregulation in the initial diabetes period (Klaassen
et al., 2009).
Concluding Remarks
An iterated concern in pericyte biology is the definition of the cell
type. The problems entailed with pericyte identification all go
back to what we mean with the term pericyte. The classical
description—and definition—is that of a quiescent pericyte in
a stable blood vessel of a normal adult organ. Yet pericyte
precursors, or the pericytes of immature and remodeling vessels
in the embryo and in pathological conditions, are also functional,
as demonstrated by the effects of their alteration or absence in
various experimental and pathological situations. Thus, the peri-
cyte is a ‘‘moving target,’’ the description and definition of which
will inevitably change and become more refined as research
moves forward. Still, the current literature is laden with reports
in which pericyte identification by morphology and marker
expression is clearly substandard, work that should therefore
be taken with a large grain of salt. Nevertheless, pericyte re-
search is currently undergoing an explosion of activity in diverse
areas of developmental and vascular biology and pathology.
Emerging concepts include the physiological role of pericytes
in the regulation of vascular permeability to solutes, molecules,
and cells, proinflammatory responses, and vascular stabilization
and normalization in tumors. The seemingly obligatory presence
of mesenchymal and other stem cells in vascular niches pose
questions about the identity of the stem cells–are some of
them pericytes, or are perciytes functional niche cells, or both?
Clearly, research on pericytes has accelerated in the past few
years and our perspectives and knowledge about these cells
will rapidly change over the years to come.Developmental Cell 21, August 16, 2011 ª2011 Elsevier Inc. 207
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